Researchers uncover key cancer-promoting gene

January 6, 2015

One of the mysteries in cancer biology is how one protein, TGF-beta, can both stop cancer from forming and encourage its aggressive growth.

Now, researchers at the University of Michigan Comprehensive Cancer Center have uncovered a key gene that may explain this paradox and provide a potential target for treatment.

TGF-beta is known as a tumor suppressor, meaning it's necessary to keep cells in check and growing normally. But at some point, its function flips and it becomes a , fostering aggressive growth and spread of cancer. The researchers identified Bub1 as a key gene involved in regulating TGF-beta receptor.

The study is published in Science Signaling.

"Our data that Bub1 is involved at the receptor level is completely unexpected," says study director Alnawaz Rehemtulla, Ph.D., Ruth Tuttle Freeman Research Professor of radiation oncology and radiology and co-director of the Center for Molecular Imaging at the University of Michigan Medical School.

"Bub1 is well-known for its role in cell division. But this is the first study that links it to TGF-beta. We think this may explain the paradox of TGF-beta as a tumor promoter and a ," he adds.

The team of researchers at the University of Michigan, including Shyam Nyati, Ph.D., and Brian D. Ross, Ph.D., developed a way to screen for genes that regulate the TGF-beta receptor. When 720 genes from the human genome were screened against and , Bub1 emerged as playing a strong role in TGF-beta signaling.

Bub1 was shown to bind to the TGF-beta receptor and allows it to turn on aggressive cell growth. When the researchers blocked Bub1, it shut down the TGF-beta pathway completely.

TGF-beta is known to play a role in cells developing characteristics of aggressive . Researchers also have known that Bub1 is highly expressed in many different types of cancer.

Because Bub1 is found in many types of cancer, developing a drug to target it could potentially impact multiple cancers. A compound to target Bub1 has been developed but is not ready for testing in patients. Initial lab testing suggests that a Bub1 inhibitor can very specifically target Bub1 without causing damage to other parts of the cell.

"When you look at gene expression in cancer, Bub1 is in the top five. In addition, Bub1 expression levels correlate with outcome in patients with lung and breast . But we never knew why. Now that we have that link, we're a step closer to shutting down this cycle," Rehemtulla says.

Explore further: Study details on-off switch that promotes or suppresses breast cancer

More information: Science Signaling, Vol. 8, Issue 358, Jan. 6, 2015.

Related Stories

Recommended for you

Epigenetic factors linked to obesity-related disease

January 17, 2017

Obesity has been linked to "letter" changes at many different sites in the genome, yet these differences do not fully explain the variation in people's body mass index (BMI) or why some overweight people develop health complications ...

Are you ready to explore baby's genome?

January 17, 2017

When you have a baby, a nurse or a phlebotomist performs a heel stick to take a few drops of blood from your infant and sends it off to a state lab for a battery of tests. Most of the time, you never hear about the results ...

Study applies game theory to genomic privacy

January 17, 2017

It comes down to privacy—biomedical research can't proceed without human genomic data sharing, and genomic data sharing can't proceed without some reasonable level of assurance that de-identified data from patients and ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shapoval
not rated yet Jan 12, 2015
Iron-Related Cancer-Promoting Genes Uncovered. Now, researchers at the University of Michigan Comprehensive Cancer Center have uncovered a key gene Bub1 involved in regulating TGF-beta receptor. Primary tumors always develop at body sites of excessive iron deposits. Local/regional iron overload can be inherited or acquired. Iron disorders are inherited and can be confirmed with genetic testing. At the cellular level, cancer occurs when cellular iron overload affects cellular organelles. Cellular iron overload can chaotically affect DNA, chromosomes, mitochondria, lysosomes, etc. The Father of Oncology recognizes that cancers are caused by iron-related genes or/and iron-related events. Chemical carcinogens, radiation, viruses, old age and some lifestyle factors non-genetically distort iron metabolism and create local/regional deposits within different tissues and organs. Clinical iron-deficiency methods will beat iron-related diseases (cancers).

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.